Qin Ning
11
3
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
27%
3 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study of MHE in Patients With Liver Diseases
Role: lead
Study on Prognosis of Acute-on-chronic Liver Failure Complicated by Bacterial or Fungal Infection
Role: lead
A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax
Role: lead
A Multicentre, Retrospective Study of Clinical Characteristics and Long-term Outcomes of Patients With Brucellosis
Role: lead
Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)
Role: lead
Clinical Observation of CABA System in the Treatment of End-stage Liver Disease With Inflammation
Role: lead
A Prospective/Retrospective, Observational Follow-up Study of Chronic Hepatitis B With Non-alcoholic Fatty Liver Disease.
Role: lead
Follow-up Study of Population Vaccinated With COVID-19 Vaccine
Role: lead
A Study of AARC Standards on Diagnosis and Treatment of Patients With HBV-ACLF in China (AARC China Study)
Role: lead
A Prospective,Observational Follow-up Study of Nucleoside Treated Patients With Chronic Hepatitis B (OCEAN Study)
Role: lead
Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients
Role: lead
All 11 trials loaded